BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on BRILINTA, talking to your doctor, and. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start . 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed.

Author: Kajilkis Brarg
Country: Barbados
Language: English (Spanish)
Genre: Love
Published (Last): 24 January 2012
Pages: 98
PDF File Size: 2.46 Mb
ePub File Size: 16.51 Mb
ISBN: 283-9-80499-864-4
Downloads: 68061
Price: Free* [*Free Regsitration Required]
Uploader: Faurn

Moderate Guarana has been shown to possess minor antiplatelet activity and, therefore, concurrent use of guarana and anticoagulants or platelet inhibitors should be avoided. After any initial dose, use with aspirin mg per day. Minor Agents, such as platelet inhibitors, that decrease clotting could decrease the efficacy of photosensitizing agents used in photodynamic therapy.

Ticagrelor is a weak inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of dihydrocodeine.

John’s Wort, Hypericum perforatum: Major Consider the use of a parenteral anti-platelet agent for patients with acute coronary syndrome who require concomitant levorphanol. Moderate Coadministration of ticagrelor and testosterone may result in increased exposure to ticagrelor which may increase the bleeding risk. Moderate An additive risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia including bexarotene.

BRILINTA® (ticagrelor) tablets Plato Trial Bleeding Data

Concomitant platelet inhibitors may increase the risk of hemorrhage. Minor Coadministration of ticagrelor and simeprevir may result in increased exposure to ticagrelor which may increase the bleeding risk. Minor Monitor for an increased incidence of etoposide-related adverse effects brilintta used concomitantly with ticagrelor. In order to decrease the risk of bleeding, discontinue ticagrelor at least 5 days prior to any surgery when possible. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Platelet transfusion did not reverse the antiplatelet effect of ticagrelor in healthy volunteers and is not likely to be of benefit in patients with bleeding.


Moderate Coadministration of ticagrelor and erythromycin may result in increased exposure to ticagrelor which may increase the bleeding risk. Ticagrelor is a sensitive CYP3A4 packaye. The maximum concentrations for ticagrelor are seen within 1. Emtricitabine; Rilpivirine; Tenofovir alafenamide: The authors concluded that fish oil supplementation in doses of 36 inseert per day does not have a statistically significant effect on the INR of patients receiving chronic warfarin therapy.

However, as a single mg intravenous dose, fosaprepitant only weakly inhibits CYP3A4 for a duration of 2 days; there is brilijta evidence of CYP3A4 induction.

BRILINTA Mechanism of Action (MOA) | BRILINTA® (ticagrelor) tablets

Patients were randomized to receive a 4-week treatment period of either placebo or 3 or 6 grams of fish oil daily. Ticagrelor is primarily metabolized by CYP3A; ticagrelor and its active metabolite brilita also P-glycoprotein P-gp substrates. Ticagrelor is a substrate and inhibitor of the hepatic isoenzyme CYP3A4 and substrate of the drug transporter P-glycoprotein P-gp ; isavuconazole, the active moiety of isavuconazonium, is a sensitive substrate and moderate inhibitor of CYP3A4 and an inhibitor of P-gp.

Because many drugs are excreted in human milk; the manufacturer recommends that ticagrelor or breast-feeding be discontinued because of the potential for serious adverse reactions in nursing infants.

PDR Search

Moderate Monitor digoxin concentrations when used concomitantly with ticagrelor. Theoretically, the risk of bleeding may be increased, but some studies that combined these agents did not produce clinically significant bleeding events.


Maintenance doses of aspirin above mg decreased ticagrelor effectiveness in a clinical trial.

Ticagrelor is also a weak CYP3A4 inhibitor. Unsert combination with caution and monitor for decreased efficacy of ticagrelor. Avoid higher aspirin maintenance doses, as ticagrelor efficacy is decreased when aspirin coadministration exceeds mg per day.

Patients receiving dialysis have not been studied. Ticagrelor is a P-glycoprotein P-gp substrate and ivacaftor is a mild P-gp inhibitor.

Moderate Monitor for an increase in ticagrelor-related adverse reactions, including bleeding, if coadministration with osimertinib is necessary. If these drugs are used together, monitor patients for suboptimal efficacy of ticagrelor as well as an increase in adverse reactions related to telotristat ethyl.

Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email is required. Other clinical data exist that describe spontaneous subdural hematomas associated with chronic Ginkgo biloba ingestion. The plasma concentrations of ticagrelor can increase when co-administered with netupitant; the inhibitory effect on CYP3A4 can last for multiple days. Ticagrelor is a P-glycoprotein P-gp substrate and verapamil is a P-gp inhibitor.

Moderate Coadministration of ticagrelor and bosutinib may result in increased exposure to ticagrelor which may increase the bleeding risk. Since there is an increased risk of subsequent cardiovascular events associated with discontinuation of ticagrelor, if possible, manage bleeding without stopping ticagrelor.

Major Consider the use of a parenteral anti-platelet agent for patients with acute coronary syndrome who require concomitant methadone.